



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/017,660	12/12/2001	Joseph S. Adorante	2873	9669
75	90 07/03/2002			
Walter A. Hackler, Ph.D. Suite B 2372 S.E. Bristol			EXAMINER	
			FAY, ZOHREH A	
Newport Beach, CA 92660-0755			ART UNIT	PAPER NUMBER
			1614	
			DATE MAILED: 07/03/2002	

Please find below and/or attached an Office communication concerning this application or proceeding.

## Office Action Summary

d

Application No. 10/017,660

Zohreh Fay

Applicant(s)

Examiner

Art Unit 1614

Adorante



	The MAILING DATE of this communication appears of	on the cover sheet with the correspondence address		
	or Reply			
THE N	ORTENED STATUTORY PERIOD FOR REPLY IS SET MAILING DATE OF THIS COMMUNICATION.	TO EXPIRE MONTH(S) FROM  so event, however, may a reply be timely filed after SIX (6) MONTHS from the		
mailing	date of this communication.			
- If NO p - Failure - Any rep	eriod for reply specified above is less than thirty (30) days, a reply within the eriod for reply is specified above, the maximum statutory period will apply ar to reply within the set or extended period for reply will, by statute, cause the ply received by the Office later than three months after the mailing date of the patent term adjustment. See 37 CFR 1.704(b).	nd will expire SIX (6) MONTHS from the mailing date of this communication.  a application to become ABANDONED (35 U.S.C. § 133).		
Status				
1) 🗆	Responsive to communication(s) filed on			
2a) 🗌	This action is <b>FINAL</b> . 2b)   ☐ This action	on is non-final.		
3) 🗆	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11; 453 O.G. 213.			
Disposit	tion of Claims			
4) 💢	Claim(s) 14-20 and 23-26	is/are pending in the application.		
4	a) Of the above, claim(s)	is/are withdrawn from consideration.		
5) 🗆	Claim(s)	is/are allowed.		
6) 💢	Claim(s) 14-20 and 23-26	is/are rejected.		
7) 🗌	Claim(s)	is/are objected to.		
8) 🗆	Claims	are subject to restriction and/or election requirement.		
Applica	tion Papers			
9) 🗆	The specification is objected to by the Examiner.			
10)	The drawing(s) filed on is/are	a) $\square$ accepted or b) $\square$ objected to by the Examiner.		
	Applicant may not request that any objection to the dr	rawing(s) be held in abeyance. See 37 CFR 1.85(a).		
11)	The proposed drawing correction filed on	is: a) $\square$ approved b) $\square$ disapproved by the Examiner		
	If approved, corrected drawings are required in reply to	o this Office action.		
12)	The oath or declaration is objected to by the Examin	ner.		
Priority	under 35 U.S.C. §§ 119 and 120			
13) 🗌	Acknowledgement is made of a claim for foreign pr	iority under 35 U.S.C. § 119(a)-(d) or (f).		
a)	☐ All b)☐ Some* c)☐ None of:			
	1. $\square$ Certified copies of the priority documents have	e been received.		
•	2. $\square$ Certified copies of the priority documents have	e been received in Application No		
	application from the International Burea			
	ee the attached detailed Office action for a list of the			
14)∐	Acknowledgement is made of a claim for domestic			
a) ∟ 15) □				
	Acknowledgement is made of a claim for domestic	priority under 30 0.3.0. 33 120 driu/or 121.		
Attachm 1) No	ent(s) tice of References Cited (PTO-892)	4) Interview Summary (PTO-413) Paper No(s).		
	tice of Draftsperson's Patent Drawing Review (PTO-948)	5) Notice of Informal Patent Application (PTO-152)		
3) [] Inf	ormation Disclosure Statement(s) (PTO-1449) Paper No(s).	6) Other:		

Application/Control Number: 10/017,660

Art Unit:

Claims 14-20 and 23-26 are presented for examination.

Claims 14-20 and 23-36 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for certain compositions which evoke biological mechanism which does not modulate aqueous humor dynamics and intraocular pressure, does not reasonably provide enablement for the broad phrase of "a pharmaceutical composition which evokes a biological mechanism which does not modulate aqueous humor dynamics and intraocular pressure". The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make or use the invention commensurate in scope with these claims. The instant specification fails to provide information that would allow the skilled artisan to practice the instant invention without undue experimentation. Attention is directed to In re Wands, 8 USPQ2d 1400 (CAFC 1988) At 1404 where the court set forth eight factors to consider when assessing if a disclosure would have required undue experimentation. Citing Ex Parte Forman, 230 USPQ 546 (BdApls 1986) at 547 the court recited eight factors:

- 1) the quantity of experiment necessary,
- 2) the amount of direction or guidance provided
- 3) the presence of absence of working example,
- 4) the nature of the invention,
- 5) the state of the prior art,
- 6) the relative skill of those in the art,
- 7) the predictability of the art, and

Application/Control Number: 10/017,660

Page 3

Art Unit:

8) the breadth of the claims.

Applicant fails to set forth the criteria that defines "a pharmaceutical composition which evokes a biological mechanism which does not modulate aqueous humor dynamics and intraocular pressure". Additionally, applicant fails to provide information allowing the skilled artisan to ascertain these compositions without undue experimentation. The instant claims read on all compositions, which evoke a biological mechanism which does not modulate aqueous humor dynamics and intraocular pressure necessitating an exhaustive search for the embodiment suitable to practice the claimed invention. Applicant fails to provide information sufficient to practice the claimed invention, absent undue experimentation.

Any inquiry concerning this communication or earlier communications from the examiner 1. should be directed to examiner Fay whose telephone number is (703) 308-4604.

> PRIMARY EXAMINER GROUP 1200 2 whet fry